23andMe

Founded in 2006, 23andMe is a prominent leader in the medical testing and clinical laboratory industry. The company specializes in direct-to-consumer genetic testing, providing users with insights into their ancestry, health predispositions, and carrier status. By leveraging a massive database of genomic information, 23andMe facilitates large-scale scientific research, bridging the gap between individual consumer healthcare and biopharmaceutical discovery. Their platform integrates advanced DNA testing technology with proprietary analytical models to advance public health knowledge and human biology research.

Operating with a workforce of 500-1,000 employees, 23andMe maintains a robust operational footprint focused on innovation in biotechnology and genomic services. The organization emphasizes professional development and a collaborative work environment to drive its research initiatives. Meet 23andMe's team to understand the leadership and scientific expertise driving their mission. The company’s product suite includes at-home test kits, genotyping services, and predictive health reports, all designed to empower individuals with actionable data. Their commitment to scientific rigor and secure data management has established them as a pioneer in the at-home genetic testing market.

Financially, 23andMe has demonstrated significant market presence, reporting annual revenue of $118.3M. The company has successfully secured substantial capital through various funding rounds, including investments from major entities like GlaxoSmithKline, Google Ventures, and New Enterprise Associates. These financial resources support their ongoing expansion into therapeutic development and clinical research. Explore financial highlights to review detailed metrics regarding their funding history and fiscal performance. As a key player in the healthcare sector, 23andMe continues to influence the intersection of consumer technology and medicalView more...